Pharmacologic HhAntag treatment resulted in about 35% tumor volume reduction after 2 weeks and a 32% decrease observed in the active nuclear form of YAP protein and also a significant decline in the protein level of stem cell marker SOX2 and survivin (a YAP down-stream effector). The gene discussed is SOX2; the disease is neoplasm.